Expert Interview
A Second Opinion: Looking at Vera Therapeutics 96-week eGFR Stabilization data in the ORIGIN Phase 2b Study of Atacicept in IgAN
Ticker(s): VERAInstitution: Northwestern Medicine
- Medical Director of the Translational Medicine Program & Professor of Medicine (Nephrology and Hypertension) and Surgery (Organ Transplantation) at Northwestern Medicine.
- Sees 500 kidney transplant patients per year.
- Research interests include the role of immunosuppressive medications in modulating the immune system, Genomic of chronic renal allograft rejection, Chronic kidney disease after liver transplant, and new immunosuppressive strategies.
Could you please explain the mechanism of action of atacicept and how it differentiates from other treatments available for IgAN, especially considering its dual inhibition of BAFF and APRIL?
Added By: ben_adminBased on the week 96 data from the Phase 2b ORIGIN study, how does atacicept's efficacy compare to other IgAN treatments?
Added By: ben_adminHow many patients with IgAN do you manage? Can you discuss the current standard of care?
Added By: ben_adminWhat are the main considerations for choosing between emerging therapies for IgA nephropathy, given the similar efficacy results, and could treatment be personalized based on patient-specific factors?
How does the combination of different treatment agents (e.g., steroids, complement inhibitors, anti-B cell agents) impact IgA nephropathy, and are there challenges in combining treatments from different companies?
Added By: catalin_adminWhat insights do we have into the efficacy of Atacicept in reducing galactose-deficient IgA1 and stabilizing eGFR, and what additional benefits could be expected from its long-term use?
Added By: catalin_adminAre there potential safety concerns, such as infection risks or immune impacts, with anti-B cell therapy like Atacicept in IgA nephropathy, especially over a longer-term follow-up?
Added By: catalin_adminWhat are potential barriers to adoption for Atacicept, including administration as a weekly subcutaneous injection and long-term safety data, and could this therapy have applications beyond IgA nephropathy?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
